According to a new report published by Allied Market Research, titled, “Fondaparinux Market – Global Opportunity Analysis and Industry Forecast, 2022-2029” Fondaparinux (Arixtra) is a synthetic anticoagulant based on the pentasaccharide sequence that makes up minimal antithrombin (AT) binding region of heparin. Similar to low molecular weight heparins, it is an indirect inhibitor of factor Xa, but it does not inhibit thrombin at all.
Fondaparinux has a longer half-life than heparin and does not interact with platelets, both of which may be advantageous in certain settings. Indications for fondaparinux include deep vein thrombosis and pulmonary embolism and superficial vein thrombosis. It is the same sequence as UFH and LMWH for the binding to antithrombin, however it has no extra chain and thus, is not considered a heparin product. It is also known to not cause HIT, as seen with UFH and LMWH.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐨𝐮𝐜𝐡𝐞𝐫: https://www.alliedmarketresearch.com/request-sample/10859
The major factor affecting the industry includes surge in product developments such that it meets the requirement posed by the market, which would help the industry in the coming years. Majority of key players are investing in product innovations and launching newer products that are cost efficient and hence are expected to help the industry gain traction during the forecast period. Furthermore, companies are focusing in mergers and acquisitions so that they are able to increase distribution channels across various regions, which is anticipated to boost the market growth.
Increase in number of mergers and acquisitions is anticipated to help the industry grow in the coming years. For instance, in September 2020, Mylan’s planned a megamerger with Pfizer’s Upjohn generics unit. Mylan will shell out $756 million for European rights to a suite of Aspen Pharmacare’s sterile injectable anticoagulants that ranked in nearly a quarter-billion dollars. The Aspen acquisition will position Mylan as one of the largest producers of thrombosis products in Europe. This would help the market to gain traction during the forecast period.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲: https://www.alliedmarketresearch.com/purchase-enquiry/10859
COVID-19 Scenario Analysis:
Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
- This study presents the analytical depiction of the global Fondaparinux industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Fondaparinux market share.
- The current market is quantitatively analyzed from 2020 to 2027 to highlight the global Fondaparinux market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global Fondaparinux market analysis based on competitive intensity and how the competition will take shape in coming years.
𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 https://www.alliedmarketresearch.com/request-for-customization/10859
Comprehensive competitive analysis and profiles of major market players such Bayer Healthcare AG, GlaxoSmithKline plc., Boehringer Ingelheim, Sanofi S.A., Apotex, Abbott India Limited, Aspen Holdings, Pfizer Inc., Bristol-Myers Squibb Company, Eisai Inc., WisMed Pharmaceuticals and Kaifeng Pharmaceutical.
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Surgical Robotic System Market: https://www.alliedmarketresearch.com/surgical-robotic-systems-market-A06827
Healthcare Interoperability Solutions Market: https://www.alliedmarketresearch.com/healthcare-interoperability-solutions-market-A07075
Surgical Drains Market https://www.alliedmarketresearch.com/wound-drainage-surgical-drains-market-A07517
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
5933 NE Win Sivers Drive
205, Portland, OR 97220
Toll Free: 1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060